For Immediate Release

Chicago, IL - April 9, 2009 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: GlaxoSmithKline plc (GSK), General Growth Properties (GGP), Agria Corp (GRO), Regis Corporation (RGS) and Ulta Salon, Cosmetics & Fragrance, Inc. (ULTA).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=4579.

Here are highlights from Wednesday's Analyst Blog:

Glaxo's Avandia Issue Priced-In

Sales of Avandia have been significantly negatively impacted due to safety concerns, but it appears they have recently stabilized. We believe that sales are now at, or very near, their bottom. While sales of Avandia have been

...

Expect Agria's Sales to Fall in 2009 Agria Corp's (GRO) financial performance through the first nine months has been hampered by significantly lower seed prices and a disruption in production of sheep-breeding products. We would not categorize the cause of either to be inherent fundamental issues that would be expected to affect sales for the long-term.Sheep-breeding revenue should continue to rebound in the fourth quarter and into 2009. While corn seed prices will likely remain depressed until the excess inventory in the market is consumed, we do not expect this to be a protracted event.Of greater concern is the global economic slowdown and how it will affect sales, profitability and cash position in 2009 and possibly into 2010. Arrangements such as upfront payments to suppliers to fund the growing and harvesting season (which is then recouped when Agria buys the product) leaves the ...

Agria Corp. (GRO) is a Chinese-based agricultural company involved in the research and development, and production and sale of three different types of upstream agricultural products; corn seeds, sheep breeding products and seedling products. The company's sales should rebound but remain below levels in the near-term due to depressed seed prices and global economic weakness. Longer term, revenue and earnings growth should be robust but we are concerned about significant governance and transparency issues.We are initiating coverage of the shares with Hold recommendation and a $2.00 price target.Read the full analyst report on GRO "GRO" Free Stock Analysis: Buy? Sell? Hold?Zacks Investment Research